Latest California Healthline Stories
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
Surprise-Billing Rule ‘Puts a Thumb on the Scale’ to Keep Arbitrated Costs in Check
Patients soon will not have to worry about the prospect of these often-costly unexpected bills, a federal law promises. Some experts say the new policy could also slow the growth of health insurance premiums.
Apple, Bose and Others Pump Up the Volume on Hearing Aid Options, Filling Void Left by FDA
A 2017 law designed to help lower the cost of hearing aids mandated that federal officials set rules for a new class of devices consumers could buy without needing to see an audiologist. But those regulations are still on hold.
2+2=? Senate Uses Murky Math as It Shelves Drug Pricing Rule to Fund Infrastructure
The Medicare rule, designed by the Trump administration to take money away from drug industry brokers and provide refunds to patients, has not been implemented. But budget analysts say if it were, it would cost the government money. So senators are pushing the rule aside and claiming to save billions of dollars, which they want to use instead on new projects.
Hospital Prices Must Now Be Transparent. For Many Consumers, They’re Still Anyone’s Guess.
A Trump administration rule mandating that hospitals disclose true prices on their websites took effect this year. But compliance is spotty and even when the data is public, it’s hard to find and understand.
KHN’s ‘What the Health?’: Un-Trumping the ACA
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act, in an effort to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive new drug that might or might not slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of The Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
KHN’s ‘What the Health?’: Picking Up the Pace of Undoing Trump Policies
The Biden administration has started to speed efforts to reverse health policies forged under Donald Trump. Most recently, the administration overturned a ban on fetal tissue research and canceled a last-minute extension of a Medicaid waiver for Texas. That latter move may delay the Senate confirmation of President Joe Biden’s nominee to head the Medicare and Medicaid programs, as Sen. John Cornyn (R-Texas) seeks to fight back. Anna Edney of Bloomberg News, Rachel Cohrs of Stat and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
Biden Moves to Overturn Trump Birth Control Rules
Return to pre-Trump policy is second win of the week for abortion-rights backers.
Redfield Joins Big Ass Fans, Which Promotes Controversial Covid-Killing Technology
Dr. Robert Redfield, Trump’s CDC director, lends his scientific credibility to its Clean Air Systems subsidiary, which touts a “virus-killing ion technology” added to its fans. But indoor air quality experts question whether some of its technology works in the real world.